ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,473.17
-0.25%
Dow Jones
39,134.76
0.77%
US Dollar vs MXN
18.359
0.02%
Brent Oil
84.885
-0.14%
Bitcoin
64,730.85
-0.14%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) Noticias

NBIX Neurocrine Biosciences Inc

134.07
3.21 (2.45%)
20 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Neurocrine Biosciences Inc NBIX NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
3.21 2.45% 134.07 18:22:43
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
129.99 129.33 135.19 134.07 130.86
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
04/6/202415:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202407:01PRNUSNeurocrine Biosciences Presented CAHtalyst™ Phase 3..
03/6/202406:35PRNUSNeurocrine Biosciences Announces Publication of Primary..
03/6/202406:30PRNUSNeurocrine Biosciences Announces Publication of Primary..
30/5/202415:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202415:53EDGAR2Form 144 - Report of proposed sale of securities
29/5/202415:01PRNUSNeurocrine Biosciences to Participate at Investor..
28/5/202415:14PRNUSNeurocrine Biosciences Announces CEO Succession Plan
28/5/202407:30PRNUSNeurocrine Biosciences to Present New Phase 3 CAHtalyst™..
23/5/202417:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202417:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202416:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/5/202415:01EDGAR2Form 8-K - Current report
21/5/202416:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202416:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202416:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202416:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202415:05PRNUSNeurocrine Biosciences Announces Publication of Phase 3..
17/5/202415:32EDGAR2Form 144 - Report of proposed sale of securities
17/5/202415:31EDGAR2Form 144 - Report of proposed sale of securities
17/5/202415:31EDGAR2Form 144 - Report of proposed sale of securities
16/5/202415:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/5/202415:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/5/202415:23EDGAR2Form 144 - Report of proposed sale of securities
14/5/202415:23EDGAR2Form 144 - Report of proposed sale of securities
14/5/202407:30PRNUSNeurocrine Biosciences Presented Baseline Data from the..
09/5/202408:45PRNUSNeurocrine Biosciences Presents CAHtalyst™ Adult Study..
09/5/202407:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
08/5/202415:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202407:30PRNUSNeurocrine Biosciences Announces Initiation of Phase 1..
07/5/202415:15PRNUSNeurocrine Biosciences to Present at the BofA Securities..
07/5/202407:30PRNUSNeurocrine Biosciences to Present Phase 3 Baseline..
06/5/202407:30PRNUSNeurocrine Biosciences Supports Tardive Dyskinesia Awareness..
03/5/202412:15PRNUSNeurocrine Biosciences Presented CAHtalyst™ Pediatric Study..
01/5/202406:00PRNUSNeurocrine Biosciences Reports First Quarter 2024 Financial..
30/4/202416:12PRNUSNeurocrine Biosciences Announces U.S. FDA Approval of..
24/4/202407:30PRNUSNeurocrine Biosciences Launches WHAT THE C@H?! Educational..
23/4/202406:00PRNUSNeurocrine Biosciences Reports Positive Phase 2 Data for..
16/4/202415:01GLOBESentia Medical Sciences and Neurocrine Biosciences Extend..
10/4/202415:01PRNUSNeurocrine Biosciences Announces Conference Call and Webcast..
03/4/202407:30PRNUSNeurocrine Biosciences Announces First-Patient Dosed in..

Su Consulta Reciente

NASDAQ
NBIX
Neurocrine Biosciences
LSE
62HO
Hsbc Bk.und.fr
DBI
DTFU
IDDAX 2X SHORT NC TR EO
NASDAQ
AXSVX
AXS Adaptive Plus Fund I...
GATE
MRCHUSDT
MerchDAO
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados